Enterococcus Faecium Infections – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：64頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Enterococcus Faecium Infections – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Enterococcus Faecium Infections - Pipeline Review, H2 2012', provides an overview of the Enterococcus Faecium Infections therapeutic pipeline. This report provides information on the therapeutic development for Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections. 'Enterococcus Faecium Infections - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Enterococcus Faecium Infections.
- A review of the Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Enterococcus Faecium Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Enterococcus Faecium Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Enterococcus Faecium Infections pipeline depth and focus of Enterococcus Faecium Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Enterococcus Faecium Infections - Pipeline Review, H2 2012', provides an overview of the Enterococcus Faecium Infections therapeutic pipeline. This report provides information on the therapeutic development for Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections. 'Enterococcus Faecium Infections - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Enterococcus Faecium Infections.
- A review of the Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Enterococcus Faecium Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Enterococcus Faecium Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Enterococcus Faecium Infections pipeline depth and focus of Enterococcus Faecium Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Enterococcus Faecium Infections Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Enterococcus Faecium Infections 8
Enterococcus Faecium Infections Therapeutics under Development by Companies 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
Enterococcus Faecium Infections Therapeutics – Products under Development by Companies 16
Companies Involved in Enterococcus Faecium Infections Therapeutics Development 17
Ceragenix Pharmaceuticals, Inc. 17
Piramal Healthcare Limited 18
Nabi Biopharmaceuticals 19
Wockhardt Limited 20
Paratek Pharmaceuticals, Inc. 21
Immtech Pharmaceuticals, Inc. 22
Lorus Therapeutics Inc 23
Oragenics, Inc. 24
MerLion Pharmaceuticals Pte Ltd 25
Aquapharm Biodiscovery Limited 26
MicuRx Pharmaceuticals, Inc. 27
Trius Therapeutics, Inc. 28
Enterococcus Faecium Infections – Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
LOR-220 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Omadacycline - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Antibiotic Program - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
MU1140 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Lipopeptide Programme - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
EnteroVAX - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
PM181104 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Tedizolid Phosphate - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Lipopeptide Program - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MRX-I - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
CSA-13 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
WCK 4086 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
MRX-II - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
SLP0905 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
SLP0904 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
AQP-182 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Enterococcus Faecium Infections Therapeutics – Drug Profile Updates 54
Enterococcus Faecium Infections Therapeutics - Dormant Products 59
Enterococcus Faecium Infections – Product Development Milestones 60
Featured News & Press Releases 60
Aug 14, 2012: Lorus Therapeutics Announces Issuance Of Patent In Japan For Antimicrobial Drug LOR-220 60
May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent 60
Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I 60
Mar 27, 2012: Lorus Therapeutics Announces Positive Results From Small Molecule Antimicrobial Program 61
Oct 21, 2010: Lorus Therapeutics Announces Allowance Of US Patent For Lead Antimicrobial Small Molecule 62
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 64
Disclaimer 64
List of Tables
Number of Products Under Development for Enterococcus Faecium Infections, H2 2012 8
Products under Development for Enterococcus Faecium Infections – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Ceragenix Pharmaceuticals, Inc., H2 2012 17
Piramal Healthcare Limited, H2 2012 18
Nabi Biopharmaceuticals, H2 2012 19
Wockhardt Limited, H2 2012 20
Paratek Pharmaceuticals, Inc., H2 2012 21
Immtech Pharmaceuticals, Inc., H2 2012 22
Lorus Therapeutics Inc, H2 2012 23
Oragenics, Inc., H2 2012 24
MerLion Pharmaceuticals Pte Ltd, H2 2012 25
Aquapharm Biodiscovery Limited, H2 2012 26
MicuRx Pharmaceuticals, Inc., H2 2012 27
Trius Therapeutics, Inc., H2 2012 28
Assessment by Monotherapy Products, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 33
Enterococcus Faecium Infections Therapeutics – Drug Profile Updates 54
Enterococcus Faecium Infections Therapeutics – Dormant Products 59
List of Figures
Number of Products under Development for Enterococcus Faecium Infections, H2 2012 8
Products under Development for Enterococcus Faecium Infections – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Discovery and Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 29
Assessment by Route of Administration, H2 2012 30
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Molecule Type, H2 2012 32
Assessment by Stage and Molecule Type, H2 2012 33
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Enterococcus Faecium Infections Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Enterococcus Faecium Infections 8
Enterococcus Faecium Infections Therapeutics under Development by Companies 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
Enterococcus Faecium Infections Therapeutics – Products under Development by Companies 16
Companies Involved in Enterococcus Faecium Infections Therapeutics Development 17
Ceragenix Pharmaceuticals, Inc. 17
Piramal Healthcare Limited 18
Nabi Biopharmaceuticals 19
Wockhardt Limited 20
Paratek Pharmaceuticals, Inc. 21
Immtech Pharmaceuticals, Inc. 22
Lorus Therapeutics Inc 23
Oragenics, Inc. 24
MerLion Pharmaceuticals Pte Ltd 25
Aquapharm Biodiscovery Limited 26
MicuRx Pharmaceuticals, Inc. 27
Trius Therapeutics, Inc. 28
Enterococcus Faecium Infections – Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
LOR-220 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Omadacycline - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Antibiotic Program - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
MU1140 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Lipopeptide Programme - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
EnteroVAX - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
PM181104 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Tedizolid Phosphate - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Lipopeptide Program - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MRX-I - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
CSA-13 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
WCK 4086 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
MRX-II - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
SLP0905 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
SLP0904 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
AQP-182 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Enterococcus Faecium Infections Therapeutics – Drug Profile Updates 54
Enterococcus Faecium Infections Therapeutics - Dormant Products 59
Enterococcus Faecium Infections – Product Development Milestones 60
Featured News & Press Releases 60
Aug 14, 2012: Lorus Therapeutics Announces Issuance Of Patent In Japan For Antimicrobial Drug LOR-220 60
May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent 60
Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I 60
Mar 27, 2012: Lorus Therapeutics Announces Positive Results From Small Molecule Antimicrobial Program 61
Oct 21, 2010: Lorus Therapeutics Announces Allowance Of US Patent For Lead Antimicrobial Small Molecule 62
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 64
Disclaimer 64
List of Tables
Number of Products Under Development for Enterococcus Faecium Infections, H2 2012 8
Products under Development for Enterococcus Faecium Infections – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Ceragenix Pharmaceuticals, Inc., H2 2012 17
Piramal Healthcare Limited, H2 2012 18
Nabi Biopharmaceuticals, H2 2012 19
Wockhardt Limited, H2 2012 20
Paratek Pharmaceuticals, Inc., H2 2012 21
Immtech Pharmaceuticals, Inc., H2 2012 22
Lorus Therapeutics Inc, H2 2012 23
Oragenics, Inc., H2 2012 24
MerLion Pharmaceuticals Pte Ltd, H2 2012 25
Aquapharm Biodiscovery Limited, H2 2012 26
MicuRx Pharmaceuticals, Inc., H2 2012 27
Trius Therapeutics, Inc., H2 2012 28
Assessment by Monotherapy Products, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 33
Enterococcus Faecium Infections Therapeutics – Drug Profile Updates 54
Enterococcus Faecium Infections Therapeutics – Dormant Products 59
List of Figures
Number of Products under Development for Enterococcus Faecium Infections, H2 2012 8
Products under Development for Enterococcus Faecium Infections – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Discovery and Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 29
Assessment by Route of Administration, H2 2012 30
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Molecule Type, H2 2012 32
Assessment by Stage and Molecule Type, H2 2012 33
